👍-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

6f1a6f45
2022-11-29

👍

【新股IPO】3D MEDICINES-B(01244)今起招股入场费13252.23港元

3D MEDICINES-B今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。

【新股IPO】3D MEDICINES-B(01244)今起招股入场费13252.23港元

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":620870046,"tweetId":"620870046","gmtCreate":1669690798187,"gmtModify":1676538224000,"author":{"id":4130472326487360,"idStr":"4130472326487360","authorId":4130472326487360,"authorIdStr":"4130472326487360","name":"6f1a6f45","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍</p></body></html>","htmlText":"<html><head></head><body><p>👍</p></body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/620870046","repostId":2287254564,"repostType":2,"repost":{"id":"2287254564","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1669681789,"share":"https://www.laohu8.com/m/news/2287254564?lang=&edition=full","pubTime":"2022-11-29 08:29","market":"hk","language":"zh","title":"【新股IPO】3D MEDICINES-B(01244)今起招股 入场费13252.23港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2287254564","media":"凤凰网港股","summary":"3D MEDICINES-B今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。","content":"<html><body><p>3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；<a href=\"https://laohu8.com/S/601995\">中金公司</a>及<a href=\"https://laohu8.com/S/601066\">中信建投</a>国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【新股IPO】3D MEDICINES-B(01244)今起招股 入场费13252.23港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【新股IPO】3D MEDICINES-B(01244)今起招股 入场费13252.23港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1002821290\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time\">2022-11-29 08:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；<a href=\"https://laohu8.com/S/601995\">中金公司</a>及<a href=\"https://laohu8.com/S/601066\">中信建投</a>国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPO":"Renaissance IPO ETF","01244":"思路迪医药股份"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=62a79e0fe0fe0a2c4d3a7e8494242b53","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2287254564","content_text":"3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。","news_type":1},"isVote":1,"tweetType":1,"viewCount":233,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}